WO2003094972A3 - Fap-activated anti-tumor prodrugs - Google Patents

Fap-activated anti-tumor prodrugs Download PDF

Info

Publication number
WO2003094972A3
WO2003094972A3 PCT/EP2003/004713 EP0304713W WO03094972A3 WO 2003094972 A3 WO2003094972 A3 WO 2003094972A3 EP 0304713 W EP0304713 W EP 0304713W WO 03094972 A3 WO03094972 A3 WO 03094972A3
Authority
WO
WIPO (PCT)
Prior art keywords
prodrugs
fap
fapα
cytotoxic
carboxylic acid
Prior art date
Application number
PCT/EP2003/004713
Other languages
French (fr)
Other versions
WO2003094972A2 (en
Inventor
Erik Patzelt
John Edward Park
Stefan Peters
Original Assignee
Boehringer Ingelheim Pharma
Erik Patzelt
John Edward Park
Stefan Peters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Erik Patzelt, John Edward Park, Stefan Peters filed Critical Boehringer Ingelheim Pharma
Priority to EP03727438A priority Critical patent/EP1506221A2/en
Priority to AU2003233238A priority patent/AU2003233238A1/en
Publication of WO2003094972A2 publication Critical patent/WO2003094972A2/en
Publication of WO2003094972A3 publication Critical patent/WO2003094972A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to prodrugs which are capable of being converted into prodrug intermediates of a cytotoxic or cytostatic drug, by the catalytic action of FAPα, said prodrugs exhibit- an oligomeric part comprising up to (9) amino carboxylic acid residues, the amide bond between the C-terminal amino carboxylic acid and the preceding amino acid thereof is recognized and cleaved by FAPα in the immediate environment of a target cell, and- a cytotoxic or cytostatic part, wherein the N-terminal amino function of the oligomeric part is attached to a capping group (Cg).
PCT/EP2003/004713 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs WO2003094972A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03727438A EP1506221A2 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs
AU2003233238A AU2003233238A1 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02010552.4 2002-05-10
EP02010552 2002-05-10

Publications (2)

Publication Number Publication Date
WO2003094972A2 WO2003094972A2 (en) 2003-11-20
WO2003094972A3 true WO2003094972A3 (en) 2004-03-18

Family

ID=29414680

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/004713 WO2003094972A2 (en) 2002-05-10 2003-05-06 Fap-activated anti-tumor prodrugs

Country Status (3)

Country Link
EP (1) EP1506221A2 (en)
AU (1) AU2003233238A1 (en)
WO (1) WO2003094972A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087131A2 (en) * 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
EP4267188A1 (en) 2020-12-22 2023-11-01 Cobiores NV Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000071571A2 (en) * 1999-05-14 2000-11-30 Boehringer Ingelheim Pharma Kg Fap-activated anti-tumor compounds
WO2002100353A2 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
WO2000071571A2 (en) * 1999-05-14 2000-11-30 Boehringer Ingelheim Pharma Kg Fap-activated anti-tumor compounds
WO2002100353A2 (en) * 2001-06-11 2002-12-19 Medarex, Inc. Cd10-activated prodrug compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BREISTOL K ET AL: "The antitumour activity of the prodrug N-l-leucyl-doxorubicin and its parent compound doxorubicin in human tumour xenografts", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 34, no. 10, September 1998 (1998-09-01), pages 1602 - 1606, XP004285055, ISSN: 0959-8049 *

Also Published As

Publication number Publication date
WO2003094972A2 (en) 2003-11-20
AU2003233238A1 (en) 2003-11-11
AU2003233238A8 (en) 2003-11-11
EP1506221A2 (en) 2005-02-16

Similar Documents

Publication Publication Date Title
IL186265A0 (en) Il-21 variants
WO2007081516A3 (en) Tumor activated prodrugs
WO2007133153A8 (en) Improved antimicrobial peptides
WO2002038742A3 (en) Dipeptidylpeptidases and methods of use
WO2007108013A3 (en) Novel bioconjugates as therapeutic agent and synthesis thereof
NZ600690A (en) Fkbp-l and uses thereof
WO2003035861A3 (en) Thrombin-cleavable chimeric proteins
HK1083345A1 (en) Process for producing dipeptides
WO2003082898A3 (en) Novel analogues of glucose-dependent insulinotropic polypeptide
EP2455462A3 (en) Lipase variants for pharmaceutical use
WO2007022512A3 (en) Glycopegylated factor vii and factor viia
WO2002000263A3 (en) Tripeptide prodrug compounds
IL180727A (en) Anti-fungal peptides comprising an arginine- and/or lysine-containing motif
WO2007094985A3 (en) Long-acting polypeptides and methods of producing and administering same
MX2010002460A (en) Complexes of rna and cationic peptides for transfection and for immunostimulation.
WO2007004876A3 (en) Peptides inhibiting angiotensin-converting enzyme
WO2003091398A3 (en) Compositions and methods for stem cell delivery
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2003094972A3 (en) Fap-activated anti-tumor prodrugs
WO2010057242A3 (en) Vaccine
ATE548380T1 (en) MUTANT OF THE HGF PRECURSOR PROTEIN AND ACTIVATED FORM THEREOF
AU2001272504A1 (en) 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof
WO2008047370A3 (en) Compositions and methods for inducing angiogenesis
ATE481420T1 (en) IL-21 DERIVATIVES
WO2004074312A3 (en) Tryptophyllin peptides and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003727438

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003727438

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003727438

Country of ref document: EP